Guidance Provided for PCPs to Identify Biliary Atresia in Newborns by 2 to 4 Weeks
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 18, 2025 -- In a clinical report issued by the American Academy of Pediatrics and published online Feb. 18 in Pediatrics, recommendations are presented to assist primary care providers in identifying biliary atresia in newborns by 2 to 4 weeks of life.
Sanjiv Harpavat, M.D., Ph.D., from Baylor College of Medicine and Texas Children's Hospital in Houston, and colleagues provide a strategy that can be used between 2 and 4 weeks of life at the "by 1 month" well-child visit in the Bright Futures/American Academy of Pediatrics "Recommendations for Preventive Pediatric Health Care."
The strategy includes examination of infant eye color, stool color, and prior laboratory results to assess whether drawing a direct or conjugated bilirubin level is warranted. Step 1 assesses whether the eyes or skin appear jaundiced beyond 2 weeks of life; the strategy proceeds to Step 2 even if the answer is no. Step 2 examines whether stools are pale, gray, or white; the strategy proceeds to Step 3 even if the answer is no. Step 3 evaluates at whether bilirubin levels were previously checked and, if so, whether the initial value was above the laboratory's range. The authors note the initial direct or conjugated bilirubin level will be high in biliary atresia, starting at birth. Skin and stool color should continue to be monitored even if the bilirubin levels were not checked or are not above the laboratory range, which could occur if compared with the wrong reference range.
"By identifying infants earlier, primary care providers have a unique opportunity to improve outcomes and help reduce the tremendous liver transplant burden of biliary atresia," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
DDW: Certain Proteins Predict Metabolic Dysfunction-Associated Steatotic Liver Disease
FRIDAY, April 25, 2025 -- Five proteins are significant predictors of metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study presented at the 2025...
Statins May Reduce Risk for Hepatocellular Carcinoma in Chronic Liver Disease
WEDNESDAY, March 19, 2025 -- For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and hepatic decompensation...
Metabolic Surgery May Be Beneficial in MASH-Related Cirrhosis, Obesity
MONDAY, Feb. 3, 2025 -- For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and obesity, metabolic surgery is associated with a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.